NCT01833546View on ClinicalTrials.gov

A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 18, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

January 25, 2016

Conditions
Solid TumorPancreatic Cancer
Interventions
DRUG

Evofosfamide

Evofosfamide infusion intravenously at an escalated dose of 240, 340 or 480 milligram per square meter (mg/m\^2) on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.

DRUG

Gemcitabine

Gemcitabine 1000 mg/m\^2 on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.

Trial Locations (2)

Unknown

Research Site, Kashiwa

Research Site, Tokyo

Sponsors

Collaborators (1)

Threshold Pharmaceuticals
All Listed Sponsors
collaborator

Threshold Pharmaceuticals

INDUSTRY

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01833546 - A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer | Biotech Hunter | Biotech Hunter